anurajms/meta_analysis huggingface dataset:
primary outcome:
Dressings and securement devices for central venous catheters (CVC)
Incidence of catheter‐related blood stream infection (BSI): as defined by one of the following three criteria.Primary bacteraemia/fungaemia with at least one positive blood culture from a peripheral vein with no other identifiable source for the BSI other than the CVC, plus, one of: a positive semiquantitative (> 15 colony‐forming units (cfu)) or quantitative (> 10³ cfu) device culture, with the same organism (species and antibiogram) isolated from the device and blood (Maki 2006; O'Grady 2002).Two blood cultures (one from an CVC hub and one from a peripheral vein), that both meet the CVC related‐BSI criteria for quantitative blood cultures (three‐fold greater colony count of growth for the same organism as from the peripheral blood), or differential time to positivity (DTP; growth of the same microbe from hub drawn blood at least two hours before growth from the peripheral blood; Mermel 2009).Two quantitative blood cultures of samples obtained through two catheter lumens in which the colony count for the blood sample drawn through one lumen is at least three‐fold greater than the colony count for the blood sample from the second lumen (Mermel 2009).
primary outcome:
Devices and dressings to secure peripheral venous catheters to prevent complications
PVC failure (a composite measure of unplanned PVC removal for any reason, such as phlebitis, infiltration accidental removal, blockage).Adverse events (such as allergic skin reaction; blisters) .
primary outcome:
Perioperative corticosteroids for preventing complications following facial plastic surgery
Swelling (oedema), measured by specific scale defined by trial authors.Bruising (ecchymosis), measured by specific scale defined by trial authors.Pain scored by validated scale, e.g. visual analogue scale (VAS).Time to complete healing of wounds.
primary outcome:
Continuous versus interrupted skin sutures for non‐obstetric surgery
Surgical site infection within 30 days of operation. We attempted to use the standard definition of surgical site infection described by Horan 1992. Otherwise, we have accepted the definitions stated by the authors of the reports.Superficial.Deep.Wound dehiscence within 30 days of operation. Postoperative wound dehiscence refers to wound disruption resulting from poor wound healing caused by various factors such as type of incision, infection, anaemia, diabetes, ascorbic acid deficiency, etc (Keill 1973). Dehiscence is classified as: superficial (dehiscence involving skin and subcutaneous tissue) or deep (burst abdomen or dehiscence of fascia).Quality of life (short‐term and long‐term; however defined by authors).
primary outcome:
Pin site care for preventing infections associated with external bone fixators and pins
Incidence of infection (as classified by Sims 1996) or other documented method
primary outcome:
Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy
Diagnosis of peristomal site infection (as defined by the study authors) up to 30 days after placement of PEG tube.
comparison group:
Skin care interventions in infants for preventing eczema and food allergy
1. Usual Care
comparison group:
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Antifungals For Systemic Use 2. Amphotericin 3. Placebo 4. Azole antifungal 5. Oral 6. Usual Care 7. Nebulizer
comparison group:
Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Placebo 2. Usual Care
comparison group:
Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children
1. Acellular Pertussis Vaccine
comparison group:
High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants
1. Enteral nutrition 2. Medium Chain Triglycerides 3. Low Dose
comparison group:
Sublingual immunotherapy for asthma
1. Placebo 2. Usual Care
comparison group:
Dilute versus full‐strength formula in exclusively formula‐fed preterm or low birth weight infants
1. Infant Formula
comparison group:
Probiotics for treating eczema
1. Placebo
comparison group:
Infant formulas containing hydrolysed protein for prevention of allergic disease
1. Infant Formula 2. Cow's Milk 3. Breast Milk
comparison group:
Oral and sublingual immunotherapy for egg allergy
1. Placebo 2. Avoidance diet
comparison group:
Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy
1. Placebo 2. Polyunsaturated Fatty Acid Supplementation
comparison group:
Specific allergen immunotherapy for the treatment of atopic eczema
1. Calcineurin inhibitor 2. Corticosteroids - Otological 3. Administration Of Drug Or Medicament To Skin Via Topical Route 4. Tacrolimus 5. Placebo 6. Usual Care 7. Application Of Emollient To Skin
comparison group:
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion
1. Red Blood Cell Transfusion
comparison group:
Immunotherapy (oral and sublingual) for food allergy to fruits
1. Placebo
comparison group:
Glycerin laxatives for prevention or treatment of feeding intolerance in very low birth weight infants
1. Placebo
comparison group:
Maternal prenatal and/or postnatal n‐3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood
1. Placebo
comparison group:
H1‐antihistamines for chronic spontaneous urticaria
1. Placebo
comparison group:
Omalizumab for asthma in adults and children
1. Placebo
comparison group:
Prebiotics in infants for prevention of allergy
1. Placebo 2. Prebiotics
comparison group:
Lactase treated feeds to promote growth and feeding tolerance in preterm infants
1. Placebo
comparison group:
Oral H1 antihistamines as monotherapy for eczema
1. Placebo 2. Topical 3. Usual Care
comparison group:
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia
1. Iron Chelating Agents 2. Placebo
comparison group:
Topical repellents for malaria prevention
1. Placebo
comparison group:
Interventions for chronic kidney disease in people with sickle cell disease
1. Placebo 2. Red Blood Cell Transfusion 3. Hydroxyurea 4. Usual Care 5. Angiotensin-converting enzyme inhibitor
comparison group:
Rapamycin and rapalogs for tuberous sclerosis complex
1. Placebo 2. Usual Care
comparison group:
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
1. Prophylaxis 2. Usual Care
comparison group:
Treatment for osteoporosis in people with beta‐thalassaemia
1. Blood Component Transfusion 2. Placebo 3. Usual Care
comparison group:
Treatment of dental and orthodontic complications in thalassaemia
1. Placebo
comparison group:
Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias
1. Foetal haemoglobin inducers 2. Placebo 3. Usual Care
comparison group:
Laser therapy for retinopathy in sickle cell disease
1. Intravitreal 2. Monoclonal Antibodies 3. Usual Care 4. Cryotherapy
comparison group:
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease
1. Usual Care
comparison group:
Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Usual Care
comparison group:
Hydroxyurea (hydroxycarbamide) for sickle cell disease
1. Placebo
comparison group:
Inhaled nitric oxide for treating pain crises in people with sickle cell disease
1. Placebo
comparison group:
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
1. Artemisinin and derivatives combinations
comparison group:
Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
1. Placebo 2. Iron Preparations 3. Oral
comparison group:
Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Usual Care
comparison group:
Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets
1. Indoor Residual Spraying 2. Mosquito Nets 3. Insecticides And Repellents
comparison group:
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
1. Placebo 2. Usual Care
comparison group:
Maternal and foetal outcomes following natural vaginal versus caesarean section (c‐section) delivery in women with bleeding disorders and carriers
1. Cesarean Section
comparison group:
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease
1. Usual Care
comparison group:
Recombinant growth hormone therapy for X‐linked hypophosphatemia in children
1. Placebo 2. Usual Care
comparison group:
Mass drug administration for malaria
1. Placebo
comparison group:
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
1. Placebo 2. Usual Care
comparison group:
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
1. Usual Care
comparison group:
Rituximab for eradicating inhibitors in people with acquired haemophilia A
1. Cytotoxic agent 2. Corticosteroids - Systemic use
comparison group:
Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B
1. Prophylaxis 2. Placebo 3. Clotting factor concentrate
comparison group:
Intermittent preventive treatment for malaria in infants
1. Placebo
comparison group:
Hematopoietic stem cell transplantation for people with β‐thalassaemia
1. Hemopoietic Stem Cell Transplant 2. Usual Care
comparison group:
Disease‐modifying treatments for primary autoimmune haemolytic anaemia
1. Support 2. Placebo 3. Usual Care
comparison group:
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
1. Placebo
comparison group:
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
1. Antimalarial
comparison group:
Interventions for treating leg ulcers in people with sickle cell disease
1. Placebo
comparison group:
Tyrosine supplementation for phenylketonuria
1. Placebo
comparison group:
Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children
1. Usual Care
comparison group:
Gene therapy for sickle cell disease
1. Usual Care
comparison group:
Phytomedicines (medicines derived from plants) for sickle cell disease
1. Placebo 2. Usual Care
comparison group:
Rituximab for treating inhibitors in people with inherited severe hemophilia
1. Intravenous 2. Placebo 3. Rituximab
comparison group:
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease
1. Preventive 2. Blood Transfusion 3. Hydroxyurea
comparison group:
Dietary interventions for phenylketonuria
1. Usual Care
comparison group:
Interventions for mycosis fungoides
1. Placebo 2. Systemic 3. Topical
comparison group:
Hematopoietic stem cell transplantation for people with sickle cell disease
1. Hemopoietic Stem Cell Transplant 2. Usual Care
comparison group:
Preoperative blood transfusions for sickle cell disease
1. Blood Transfusion 2. Preoperative
comparison group:
Interventions for treating intrahepatic cholestasis in people with sickle cell disease
1. Activated Charcoal 2. Rifampicin 3. Dexamethasone 4. Exchange Transfusion 5. Opiate antagonist 6. Guar gum 7. Liver transplant 8. Red Blood Cell Transfusion 9. Bile Acid Sequestrants 10. Sertraline
comparison group:
Growth hormone therapy for people with thalassaemia
1. Placebo
comparison group:
Vitamin D supplementation for sickle cell disease
1. Placebo 2. Oral 3. Vitamin D and analogues
comparison group:
Gene therapy for haemophilia
1. Usual Care
comparison group:
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
1. Preventive 2. Hemopoietic Stem Cell Transplant 3. Placebo 4. Hydroxyurea 5. Red Blood Cell Transfusion 6. Usual Care
comparison group:
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease
1. Non-Pharmacological Interventions 2. Placebo 3. Usual Care
comparison group:
Early erythropoiesis‐stimulating agents in preterm or low birth weight infants
1. Placebo
comparison group:
Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants
1. Placebo 2. Iron Preparations
comparison group:
Blood transfusions for treating acute chest syndrome in people with sickle cell disease
1. Usual Care
comparison group:
Intravenous iron therapy for non‐anaemic, iron‐deficient adults
1. Intravenous Infusion Of Iron 2. Intravenous 3. Placebo
comparison group:
Treatment of dental complications in sickle cell disease
1. Placebo 2. Usual Care
comparison group:
Treatment for avascular necrosis of bone in people with sickle cell disease
1. Bone Graft 2. Joint reconstruction 3. Osteotomy 4. Autogenous Vascularized Bone Graft 5. Physiotherapy 6. Electrical stimulation 7. Bisphosphonates 8. Restriction Of Movement 9. Stem Cell Transplantation 10. General Observation 11. Analgesics 12. Red Blood Cell Transfusion 13. Decompression Of Joint
comparison group:
Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures
1. Perioperative 2. Antifibrinolytics 3. Hemostatic agent 4. Colloids 5. Prophylaxis 6. Placebo 7. Plasma transfusion 8. Prothrombin Complex Concentrate 9. Cryoprecipitate 10. Fibrinogen Concentrate 11. Recombinant FVIIa 12. Crystalloids
comparison group:
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis
1. Bortezomib 2. Lenalidomide 3. Thalidomide
comparison group:
Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults
1. Pharmacotherapy 2. Placebo
comparison group:
Statins for children with familial hypercholesterolemia
1. Lipid Modifying Agents 2. Dietary Regime 3. Placebo 4. Statins
comparison group:
Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease
1. Hydroxycarbamide 2. Usual Care
comparison group:
Antibiotics for treating osteomyelitis in people with sickle cell disease
1. Antibiotic Therapy
comparison group:
Splenectomy for people with thalassaemia major or intermedia
1. Splenectomy 2. Usual Care
comparison group:
Magnesium for treating sickle cell disease
1. Placebo
comparison group:
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions
1. Placebo 2. Usual Care
comparison group:
Hydroxyurea (hydroxycarbamide) for transfusion‐dependent β‐thalassaemia
1. Iron Chelating Agents 2. Blood Transfusion 3. Hydroxyurea 4. Usual Care
comparison group:
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders
1. Factor VIII Assay 2. Tranexamic Acid 3. Fresh Frozen Plasma Transfusion 4. Clotting Factor VII Assay
comparison group:
Aerobic physical exercise for adult patients with haematological malignancies
1. Usual Care
comparison group:
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition
1. Placebo
comparison group:
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer
1. Antibiotic Therapy
comparison group:
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
1. Intravenous 2. Fresh Frozen Plasma Transfusion
comparison group:
Vaccines for preventing invasive salmonella infections in people with sickle cell disease
1. Preventive 2. Salmonella Vaccination 3. Placebo
comparison group:
Insecticide‐treated nets for preventing malaria
1. Sham Intervention
comparison group:
Drugs for preventing red blood cell dehydration in people with sickle cell disease
1. Preventive
comparison group:
Prophylactic platelet transfusions prior to surgery for people with a low platelet count
1. Romiplostim 2. Antifibrinolytics 3. Eltrombopag 4. Cryosurgery 5. Placebo 6. Oral 7. Injection
comparison group:
Conjugate Haemophilus influenzae type b vaccines for sickle cell disease
1. Haemophilus Influenzae Type B Vaccination 2. Placebo
comparison group:
Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (non‐APL))
1. Chemotherapy
comparison group:
Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders
1. Intravenous 2. Prophylaxis 3. Platelet transfusion
comparison group:
Folate supplementation in people with sickle cell disease
1. Dietary substance 2. Placebo 3. Folic Acid Supplementation
comparison group:
Mosquito repellents for malaria prevention
1. Placebo
comparison group:
Bisphosphonates in multiple myeloma: an updated network meta‐analysis
1. Placebo 2. Bisphosphonates
comparison group:
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours
1. Placebo 2. Thrombolytic agent
comparison group:
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease
1. Blood Transfusion
comparison group:
Hematopoietic stem cell transplantation for Gaucher disease
1. Substrate Reduction Therapy 2. Enzymes for alimentary tract and metabolism
comparison group:
Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn
1. Placebo
comparison group:
Thrombopoietin mimetics for patients with myelodysplastic syndromes
1. Placebo 2. Thrombolytic agent
comparison group:
Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation
1. Preventive 2. Plasma transfusion
comparison group:
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
1. Recombinant Antihemophilic Factor VIII 2. Prophylaxis 3. Prothrombin Complex Concentrate
comparison group:
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis
1. Chemotherapy 2. Radiotherapy
comparison group:
Deferasirox for managing iron overload in people with thalassaemia
1. Iron Chelating Agents 2. Placebo
comparison group:
Fluid replacement therapy for acute episodes of pain in people with sickle cell disease
1. Body Fluid Replacement
comparison group:
Pathogen‐reduced platelets for the prevention of bleeding
1. Platelet transfusion
comparison group:
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
1. ABVD 2. Radiotherapy
comparison group:
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
1. Chemotherapy 2. Radiotherapy
comparison group:
Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
1. Low Molecular Weight Heparin
comparison group:
Exercise for haemophilia
1. Physical therapy exercises
comparison group:
Antibiotics for treating community‐acquired pneumonia in people with sickle cell disease
1. Antibiotic Therapy
comparison group:
Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias
1. Placebo 2. Hydroxyurea 3. Usual Care
comparison group:
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review
1. Placebo
comparison group:
Bisphosphonate therapy for osteogenesis imperfecta
1. Placebo
comparison group:
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications
1. Self-care practice
comparison group:
Bortezomib for the treatment of multiple myeloma
1. Bortezomib
comparison group:
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
1. Preventive 2. Placebo 3. Aminocaproic Acid
comparison group:
Subsidising artemisinin‐based combination therapy in the private retail sector
1. Usual Care
comparison group:
Oral iron supplements for children in malaria‐endemic areas
1. Antimalarial 2. Placebo
comparison group:
Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
1. Chemotherapy 2. Placebo 3. Erythropoietin Therapy
comparison group:
Piracetam for reducing the incidence of painful sickle cell disease crises
1. Placebo 2. Usual Care
comparison group:
Meditation for adults with haematological malignancies
1. Usual Care
comparison group:
Washed versus unwashed red blood cells for transfusion for the prevention of morbidity and mortality in preterm infants
1. Red Blood Cell Transfusion
comparison group:
Antibody therapies for lymphoma in children
1. Usual Care
comparison group:
Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
1. Antibiotic Therapy
comparison group:
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease
1. Placebo 2. Usual Care
comparison group:
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
1. Factor IX 2. Factor VIII Assay
comparison group:
Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
1. Platelet transfusion
comparison group:
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Platelet transfusion
comparison group:
Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission
1. Chemotherapy 2. Placebo 3. Usual Care
comparison group:
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Platelet transfusion 2. High Dose 3. Standard Dose
comparison group:
Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma
1. Colony Stimulating Factors 2. Hemopoietic Stem Cell Transplant 3. Placebo
comparison group:
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders
1. Allogeneic Blood Bag 2. Red Blood Cell Transfusion
comparison group:
A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Placebo 2. Platelet transfusion
comparison group:
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
1. Anthracyclines And Related Substances
comparison group:
Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell transplantation
1. Placebo
comparison group:
Psychological therapies for sickle cell disease and pain
1. Usual Care
comparison group:
Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis
1. Placebo 2. Usual Care
comparison group:
Sapropterin dihydrochloride for phenylketonuria
1. Placebo
comparison group:
Enzyme replacement and substrate reduction therapy for Gaucher disease
1. Enzymes for alimentary tract and metabolism 2. Miglustat
comparison group:
Protein substitute for children and adults with phenylketonuria
1. Protein Supplements
comparison group:
Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria
1. Artemisinin and derivatives combinations
comparison group:
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery
1. Preventive 2. Hemostatic agent 3. Other Hematological Agents
comparison group:
Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma
1. Usual Care
comparison group:
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
1. Placebo
comparison group:
Deferasirox for managing iron overload in people with myelodysplastic syndrome
1. Iron Chelating Agents 2. Placebo
comparison group:
Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
1. Placebo
comparison group:
Interventions for treating acute bleeding episodes in people with acquired hemophilia A
1. Factor VIII Inhibitor Bypassing Activity 2. Decompression
comparison group:
Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic hematopoietic stem cell transplantation
1. Methotrexate
comparison group:
The role of additional radiotherapy for primary central nervous system lymphoma
1. Chemotherapy
comparison group:
Deferasirox for managing transfusional iron overload in people with sickle cell disease
1. Iron Chelating Agents 2. Placebo
comparison group:
Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
1. Artemisinin and derivatives combinations
comparison group:
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
1. Primaquine 2. Chloroquine
comparison group:
Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria
1. Antimalarial
comparison group:
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment
1. Cancer immunotherapy 2. Chemotherapy 3. Surgical Removal 4. Radiotherapy
comparison group:
Hyperbaric oxygen therapy for late radiation tissue injury
1. Usual Care
comparison group:
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
1. Chemotherapy 2. Supportive care 3. Immunological Therapy
comparison group:
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
1. Chemotherapy 2. Doxorubicin Hydrochloride Liposome 3. Placebo 4. Platinum Combination Chemotherapy
comparison group:
Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy
1. Radical Resection Of Soft Tissue
comparison group:
Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery
1. Usual Care
comparison group:
First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis
1. Placebo
comparison group:
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
1. Chemotherapy 2. Angiogenesis inhibitor
comparison group:
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk
1. Screening Mammography
comparison group:
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer
1. Placebo 2. General Treatment
comparison group:
Skin‐sparing mastectomy for the treatment of breast cancer
1. Simple mastectomy
comparison group:
Exercise interventions for adults with cancer receiving radiation therapy alone
1. Usual Care
comparison group:
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
1. Radiotherapy
comparison group:
Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery
1. Oral Antibiotic Therapy 2. Mechanical bowel preparation 3. Placebo
comparison group:
Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer
1. Placebo 2. Supportive care 3. Active control
comparison group:
Neoadjuvant treatment for stage III and IV cutaneous melanoma
1. Placebo 2. Usual Care
comparison group:
Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer
1. Chemotherapy 2. Placebo 3. Radiotherapy
comparison group:
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer
1. Antifungals For Systemic Use
comparison group:
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
1. Placebo 2. Usual Care 3. Waiting list control
comparison group:
Preoperative exercise training for people with non‐small cell lung cancer
1. Usual Care
comparison group:
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
1. Anthracycline 2. Placebo
comparison group:
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer
1. Chemotherapy 2. Hysterectomy 3. Radiotherapy
comparison group:
Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care
1. Mu-opioid Receptor Antagonist 2. Placebo 3. Usual Care
comparison group:
Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
1. Surgery
comparison group:
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer
1. Radiochemotherapy: To Stop Spread 2. External Beam With Internal Radiotherapy 3. Radiotherapy
comparison group:
Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
1. Lose dose computed tomography 2. Cancer screening
comparison group:
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
1. Taxanes
comparison group:
Oxycodone for cancer‐related pain
1. Oxycodone 2. Placebo
comparison group:
Perioperative enhanced recovery programmes for women with gynaecological cancers
1. Usual Care
comparison group:
Gases for establishing pneumoperitoneum during laparoscopic abdominal surgery
1. Therapeutic Insufflation 2. Medical Gases 3. Surgical Pneumoperitoneum 4. Carbon Dioxide
comparison group:
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
1. Paclitaxel 2. Carboplatin
comparison group:
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
1. Chemotherapy
comparison group:
Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy
1. Retrocolic reconstruction
comparison group:
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Usual Care
comparison group:
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
1. Anaplastic lymphoma kinase inhibitors 2. Crizotinib 3. Chemotherapy
comparison group:
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
1. Usual Care
comparison group:
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
1. Chemotherapy 2. Surgery 3. Usual Care 4. Radiotherapy
comparison group:
Prophylactic abdominal drainage for pancreatic surgery
1. Abdominal Drain
comparison group:
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
1. Support 2. Radical radiotherapy 3. Placebo
comparison group:
Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer
1. Transurethral resection of bladder tumour 2. White light cytoscopy
comparison group:
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
1. 5-HT3 Receptor Antagonist 2. Corticosteroids 3. Neurokinin 1 receptor antagonist
comparison group:
Perioperative systemic nonsteroidal anti‐inflammatory drugs (NSAIDs) in women undergoing breast surgery
1. Analgesics 2. Placebo
comparison group:
Music interventions for improving psychological and physical outcomes in people with cancer
1. Psychosocial Intervention Strategy 2. Placebo 3. Usual Care
comparison group:
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
1. Usual Care
comparison group:
Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer
1. Heparin Irrigation Solution
comparison group:
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
1. Usual Care
comparison group:
School‐based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6 to 18
1. Usual Care
comparison group:
Roux‐en‐Y versus Billroth‐I reconstruction after distal gastrectomy for gastric cancer
1. Billroth I Gastric Antrectomy
comparison group:
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma
1. Chemotherapy 2. Placebo
comparison group:
Interventions targeted at women to encourage the uptake of cervical screening
1. Usual Care
comparison group:
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma
1. Chemotherapy
comparison group:
Partial breast irradiation versus whole breast radiotherapy for early breast cancer
1. Hypofractionated Radiation Therapy 2. Whole Breast Radiation Therapy
comparison group:
Hydromorphone for cancer pain
1. Opioids 2. Placebo 3. Morphine
comparison group:
Degarelix for treating advanced hormone‐sensitive prostate cancer
1. Androgen Deprivation Therapy
comparison group:
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer
1. Physiotherapy 2. Usual Care
comparison group:
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer
1. Neo-adjuvant 2. Chemotherapy 3. Interventional Debulking Surgery
comparison group:
Protons versus photons for the treatment of chordoma
1. Megavoltage Radiation Therapy Using Photons
comparison group:
Intravesical gemcitabine for non‐muscle invasive bladder cancer
1. Drug Therapy 2. Placebo 3. Intravesical 4. BCG vaccine
comparison group:
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
1. Chemotherapy 2. Bevacizumab
comparison group:
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
1. Chemotherapy
comparison group:
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
1. Cytotoxic agent
comparison group:
Exercise for cancer cachexia in adults
1. Nutrition Therapy 2. Usual Care
comparison group:
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
1. Chemotherapy 2. Surgery 3. Placebo 4. Targeted Therapy 5. Radiotherapy 6. Angiogenesis inhibitor
comparison group:
Paravertebral anaesthesia with or without sedation versus general anaesthesia for women undergoing breast cancer surgery
1. General Anesthesia
comparison group:
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
1. Experimental Therapeutic Procedure 2. Chemotherapy 3. Surgery 4. Palliative Care 5. Usual Care 6. Radiotherapy
comparison group:
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
1. Surveillance
comparison group:
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
1. Androgen Deprivation Therapy
comparison group:
Body weight management in overweight and obese breast cancer survivors
1. Placebo 2. Waiting list control
comparison group:
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
1. Placebo 2. Other Drugs Affecting Bone Structure And Mineralization 3. Bisphosphonates
comparison group:
Platinum‐containing regimens for triple‐negative metastatic breast cancer
1. Chemotherapy
comparison group:
Targeted therapy for metastatic renal cell carcinoma
1. Cytokine Therapy 2. Placebo 3. Targeted Therapy 4. Hormone Therapy
comparison group:
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
1. Placebo
comparison group:
The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with advanced illness and their caregivers
1. Usual Care
comparison group:
Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
1. Incision Of Space Of Retzius 2. Laparoscopic Radical Prostatectomy Using Robotic Assistance
comparison group:
Helicobacter pylori eradication for the prevention of gastric neoplasia
1. Placebo
comparison group:
Radical prostatectomy versus deferred treatment for localised prostate cancer
1. Active Monitoring 2. Conservative Therapy
comparison group:
Telephone interventions for symptom management in adults with cancer
1. Usual Care 2. Medical Consultation With Outpatient
comparison group:
Surgery versus radical endotherapies for early cancer and high‐grade dysplasia in Barrett's oesophagus
1. Surgery 2. Curative
comparison group:
External beam radiation dose escalation for high grade glioma
1. Usual Care 2. Fractionated Dose Stereotactic Radiosurgery Using Linear Accelerator System
comparison group:
Physical activity interventions for disease‐related physical and mental health during and following treatment in people with non‐advanced colorectal cancer
1. Usual Care
comparison group:
Interventions for the management of malignant pleural effusions: a network meta‐analysis
1. Placebo
comparison group:
Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer
1. Usual Care
comparison group:
Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer
1. Chemotherapy 2. Clinical Observation Regime 3. Tamoxifen
comparison group:
Drugs for preventing lung cancer in healthy people
1. Placebo
comparison group:
Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Waiting list control
comparison group:
Hormone replacement therapy after surgery for epithelial ovarian cancer
1. Placebo
comparison group:
Drug therapy for delirium in terminally ill adults
1. Placebo 2. Usual Care 3. Waiting list control
comparison group:
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
1. Preventive 2. Intravenous Infusion 3. Platinum Compounds
comparison group:
Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas
1. Postoperative Course Of Radiotherapy 2. Delayed Treatment
comparison group:
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
1. Chemotherapy 2. Carboplatin
comparison group:
Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer
1. Instillation Of Mitomycin C Into Bladder 2. Intravesical
comparison group:
Interval brain imaging for adults with cerebral glioma
1. Diagnostic imaging
comparison group:
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
1. Placebo 2. Human Papillomavirus Vaccine
comparison group:
Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors
1. Shared Care 2. General Practitioner 3. Follow-up Consultation 4. Usual Care 5. Nurse
comparison group:
Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
1. Perioperative 2. Placebo 3. Antibiotic Prophylaxis 4. Preoperative
comparison group:
Follow‐up strategies for patients treated for non‐metastatic colorectal cancer
1. Postoperative Follow-up Visit 2. Individual General Health Examination
comparison group:
Taxanes for adjuvant treatment of early breast cancer
1. Chemotherapy
comparison group:
Hypofractionation for clinically localized prostate cancer
1. Radiotherapy
comparison group:
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
1. Prophylaxis 2. Placebo 3. Hospital 4. Low Molecular Weight Heparin
comparison group:
Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma
1. Chemotherapy 2. Low Dose 3. Usual Care 4. Radiotherapy
comparison group:
Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of hospital stay and postoperative complications
1. Usual Care
comparison group:
Psychosocial interventions for informal caregivers of people living with cancer
1. Usual Care
comparison group:
Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
1. Usual Care
comparison group:
Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
1. Delayed Treatment 2. Androgen Deprivation Therapy
comparison group:
Perioperative nutrition for the treatment of bladder cancer by radical cystectomy
1. Usual Care
comparison group:
Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
1. General Observation 2. Placebo
comparison group:
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
1. Pelvic Lymphadenectomy
comparison group:
Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer
1. Placebo 2. Platinum Compounds
comparison group:
Risk‐reducing medications for primary breast cancer: a network meta‐analysis
1. Placebo
comparison group:
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
1. Cancer immunotherapy 2. Chemotherapy 3. Transplantation Of Autologous Hematopoietic Stem Cell 4. Monoclonal Antibodies
comparison group:
Robotic versus open radical cystectomy for bladder cancer in adults
1. Radical Cystectomy
comparison group:
Mindfulness‐based stress reduction for women diagnosed with breast cancer
1. Usual Care
comparison group:
Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer
1. Usual Care
comparison group:
Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event
1. Oral Antibiotic Therapy 2. Inpatient Environment 3. Intravenous Antibiotic Therapy
comparison group:
Palliative interventions for controlling vaginal bleeding in advanced cervical cancer
1. Radiotherapy
comparison group:
Psychological interventions for parents of children and adolescents with chronic illness
1. Usual Care 2. Psychoeducation 3. Waiting list control
comparison group:
Intralesional treatment versus wide resection for central low‐grade chondrosarcoma of the long bones
1. Amputation 2. Wide Resection
comparison group:
Non‐invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
1. Chest Physiotherapy 2. Breathing Exercises 3. Incentive Spirometry 4. Oxygen Therapy
comparison group:
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
1. Fertility Preservation Procedure 2. Gonadotropin Releasing Hormone Agonist 3. Placebo 4. Anti-gonadotropin-releasing Hormones
comparison group:
Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults
1. Placebo
comparison group:
Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment
1. Placebo 2. Usual Care
comparison group:
Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults
1. Transarterial chemoembolization of hepatic artery
comparison group:
Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa)
1. Radical Hysterectomy
comparison group:
De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV‐positive oropharyngeal carcinoma
1. Chemotherapy 2. Adjuvant 3. Radiotherapy
comparison group:
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery
1. Usual Care
comparison group:
Anti‐angiogenic therapy for high‐grade glioma
1. Chemotherapy 2. Placebo 3. Usual Care
comparison group:
Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer
1. Chemotherapy
comparison group:
Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer
1. Placebo 2. Usual Care
comparison group:
Laparoscopy versus laparotomy for the management of early stage endometrial cancer
1. Total Laparoscopic Hysterectomy 2. Laparoscopic-assisted Vaginal Hysterectomy
comparison group:
Extended‐field radiotherapy for locally advanced cervical cancer
1. Radiochemotherapy: To Stop Spread 2. Neo-adjuvant 3. Chemotherapy 4. Radiotherapy
comparison group:
Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
1. Androgen Deprivation Therapy
comparison group:
Epidermal growth factor receptor blockers for the treatment of ovarian cancer
1. Chemotherapy
comparison group:
Exercise for reducing falls in people living with and beyond cancer
1. Usual Care
comparison group:
Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer
1. Radiochemotherapy: To Stop Spread
comparison group:
Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma
1. Procedure On Rectum
comparison group:
Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults
1. Serotonin (5ht3) Antagonists 2. Placebo 3. Usual Care 4. Prokinetic Agent 5. Other Antiemetics
comparison group:
Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer
1. Probiotics 2. General Observation 3. Placebo 4. Usual Care
comparison group:
Immunonutrition for patients undergoing surgery for head and neck cancer
1. Usual Care 2. Nutritional supplement
comparison group:
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations
1. Usual Care
comparison group:
Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis
1. Stereotactic Radiotherapy 2. Linear Accelerator System 3. Remote Radiation Robotic Handling System 4. Gamma Knife 5. Stereotactic Radiosurgery